Koutif Therapeutics

Koutif Therapeutics is a private, pre-clinical stage biotech founded in 2021 and based in Cambridge, Massachusetts. The company is pioneering a novel approach to treating inflammatory diseases and oncology by developing small molecule inhibitors of the Fbxo3 protein, a previously untargeted E3 ligase within the ubiquitin-proteasome system. By inhibiting Fbxo3, Koutif's compounds aim to promote the degradation of key pro-inflammatory proteins like TRAFs and components of the NLRP3 inflammasome, potentially offering a new therapeutic mechanism for a wide range of conditions. The company is currently in the research and development phase, building on licensed academic discoveries to advance its pipeline.

Small molecule platform targeting the ubiquitin-proteasome pathway, specifically inhibiting the Fbxo3 E3 ligase to promote degradation of pro-inflammatory proteins (TRAFs, NLRP3 inflammasome components).

The inflammatory disease space is crowded with biologics and small molecules targeting cytokines and signaling pathways. Koutif's differentiation lies in its novel upstream target. In oncology, competition includes approved proteasome inhibitors and a new generation of targeted protein degraders (e.g., PROTACs).